S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   165.02 (-1.21%)
MSFT   401.42 (-0.70%)
META   487.91 (-2.77%)
GOOGL   154.64 (-0.88%)
AMZN   176.10 (-1.74%)
TSLA   149.52 (-0.27%)
NVDA   821.64 (-2.96%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.86 (-0.03%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   150.69 (-1.47%)
CGC   8.04 (+2.68%)
DIS   111.69 (-0.66%)
AMC   3.19 (+9.25%)
PFE   25.81 (+1.65%)
PYPL   62.05 (-0.08%)
XOM   120.04 (+1.28%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   165.02 (-1.21%)
MSFT   401.42 (-0.70%)
META   487.91 (-2.77%)
GOOGL   154.64 (-0.88%)
AMZN   176.10 (-1.74%)
TSLA   149.52 (-0.27%)
NVDA   821.64 (-2.96%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.86 (-0.03%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   150.69 (-1.47%)
CGC   8.04 (+2.68%)
DIS   111.69 (-0.66%)
AMC   3.19 (+9.25%)
PFE   25.81 (+1.65%)
PYPL   62.05 (-0.08%)
XOM   120.04 (+1.28%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   165.02 (-1.21%)
MSFT   401.42 (-0.70%)
META   487.91 (-2.77%)
GOOGL   154.64 (-0.88%)
AMZN   176.10 (-1.74%)
TSLA   149.52 (-0.27%)
NVDA   821.64 (-2.96%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.86 (-0.03%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   150.69 (-1.47%)
CGC   8.04 (+2.68%)
DIS   111.69 (-0.66%)
AMC   3.19 (+9.25%)
PFE   25.81 (+1.65%)
PYPL   62.05 (-0.08%)
XOM   120.04 (+1.28%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   165.02 (-1.21%)
MSFT   401.42 (-0.70%)
META   487.91 (-2.77%)
GOOGL   154.64 (-0.88%)
AMZN   176.10 (-1.74%)
TSLA   149.52 (-0.27%)
NVDA   821.64 (-2.96%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.86 (-0.03%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   150.69 (-1.47%)
CGC   8.04 (+2.68%)
DIS   111.69 (-0.66%)
AMC   3.19 (+9.25%)
PFE   25.81 (+1.65%)
PYPL   62.05 (-0.08%)
XOM   120.04 (+1.28%)
Free Trial

Kezar Life Sciences (KZR) Competitors

→ Start loving Mondays like this (From DTI) (Ad)
Free KZR Stock Alerts
$0.78
0.00 (-0.53%)
(As of 11:38 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability

KZR vs. VAXX, GMTX, RPHM, FIXX, VHAQ, IMRX, CKPT, HCWB, SCYX, and EGRX

Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Vaxxinity (VAXX), Gemini Therapeutics (GMTX), Reneo Pharmaceuticals (RPHM), Homology Medicines (FIXX), Viveon Health Acquisition (VHAQ), Immuneering (IMRX), Checkpoint Therapeutics (CKPT), HCW Biologics (HCWB), SCYNEXIS (SCYX), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical preparations" industry.

Kezar Life Sciences vs.

Vaxxinity (NASDAQ:VAXX) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability.

Vaxxinity currently has a consensus target price of $7.00, indicating a potential upside of 1,406.02%. Kezar Life Sciences has a consensus target price of $11.00, indicating a potential upside of 1,296.65%. Given Kezar Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Vaxxinity is more favorable than Kezar Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxxinity
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Kezar Life Sciences
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Vaxxinity has a beta of 2.39, suggesting that its stock price is 139% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.

Kezar Life Sciences received 128 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 57.83% of users gave Kezar Life Sciences an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote.

CompanyUnderperformOutperform
VaxxinityOutperform Votes
5
38.46%
Underperform Votes
8
61.54%
Kezar Life SciencesOutperform Votes
133
57.83%
Underperform Votes
97
42.17%

83.0% of Vaxxinity shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 59.1% of Vaxxinity shares are owned by company insiders. Comparatively, 7.9% of Kezar Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Kezar Life Sciences had 3 more articles in the media than Vaxxinity. MarketBeat recorded 3 mentions for Kezar Life Sciences and 0 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.31 beat Kezar Life Sciences' score of 0.00 indicating that Kezar Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Vaxxinity Neutral
Kezar Life Sciences Neutral

Vaxxinity's return on equity of -43.08% beat Kezar Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
VaxxinityN/A -192.58% -88.04%
Kezar Life Sciences N/A -43.08%-37.59%

Vaxxinity has higher earnings, but lower revenue than Kezar Life Sciences. Vaxxinity is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaxxinity$70K841.62-$56.93M-$0.45-1.03
Kezar Life Sciences$7M8.19-$101.87M-$1.41-0.56

Summary

Vaxxinity and Kezar Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Kezar Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KZR vs. The Competition

Export to Excel
MetricKezar Life SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$59.45M$6.51B$4.79B$7.48B
Dividend YieldN/A3.13%2.98%4.00%
P/E Ratio-0.568.07191.6415.38
Price / Sales8.19308.692,563.7984.02
Price / CashN/A20.2946.8734.89
Price / Book0.315.444.584.19
Net Income-$101.87M$143.31M$103.64M$214.15M
7 Day Performance-8.71%-5.69%-3.80%-3.31%
1 Month Performance-9.55%-8.04%-5.31%-3.82%
1 Year Performance-68.50%-5.50%7.35%3.74%

Kezar Life Sciences Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VAXX
Vaxxinity
1.1797 of 5 stars		$0.44
-2.2%		$7.00
+1,491.6%		-78.1%$55.75M$70,000.00-0.9887Gap Up
GMTX
Gemini Therapeutics
0 of 5 stars		$30.52
-4.1%		N/A+18.2%$58.49MN/A-30.5231Gap Up
High Trading Volume
RPHM
Reneo Pharmaceuticals
0.8736 of 5 stars		$1.65
-0.6%		$18.14
+999.2%		-78.6%$55.14MN/A-0.6555Gap Down
FIXX
Homology Medicines
1.4934 of 5 stars		$0.93
+0.8%		$0.75
-19.8%		N/A$54.33M$1.16M-0.487
VHAQ
Viveon Health Acquisition
0 of 5 stars		$9.00
flat		N/AN/A$59.85MN/A0.00N/AGap Up
IMRX
Immuneering
3.7888 of 5 stars		$1.84
-3.7%		$13.50
+633.7%		-86.8%$53.88M$320,000.00-0.9768Gap Up
CKPT
Checkpoint Therapeutics
3.1547 of 5 stars		$1.69
-1.7%		$22.60
+1,237.3%		-43.1%$60.32M$100,000.00-0.5124Gap Up
HCWB
HCW Biologics
0 of 5 stars		$1.60
-1.2%		$9.00
+462.5%		+11.4%$60.51M$2.84M-2.2945Positive News
SCYX
SCYNEXIS
2.858 of 5 stars		$1.41
-4.1%		$15.00
+963.8%		-56.6%$53.23M$140.14M1.0736Positive News
EGRX
Eagle Pharmaceuticals
3.66 of 5 stars		$4.69
-9.8%		$17.00
+262.5%		-83.9%$60.92M$316.61M3.97134Gap Up

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:KZR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Urgent alert: open this for a huge profit potential
Timothy Sykes